Cellectis S.A. (CMVLF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -108.85 Million USD | -21.4% |
| 2022 | -89.66 Million USD | -4.95% |
| 2021 | -85.43 Million USD | 0.0% |
| 2020 | -85.43 Million USD | 30.85% |
| 2019 | -123.55 Million USD | -17.57% |
| 2018 | -105.09 Million USD | -13.43% |
| 2017 | -92.65 Million USD | -44.85% |
| 2016 | -63.96 Million USD | -109.51% |
| 2015 | -30.52 Million USD | -378.67% |
| 2014 | -6.37 Million USD | 92.09% |
| 2013 | -80.62 Million USD | -208.43% |
| 2012 | -26.13 Million USD | -3.29% |
| 2011 | -25.3 Million USD | -65.97% |
| 2010 | -15.24 Million USD | -12.99% |
| 2009 | -13.49 Million USD | -181.31% |
| 2008 | -4.79 Million USD | 38.35% |
| 2007 | -7.78 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -22.76 Million USD | 27.86% |
| 2024 Q2 | -23.86 Million USD | -4.84% |
| 2023 Q1 | -23.43 Million USD | -313.98% |
| 2023 Q3 | -20.67 Million USD | 12.63% |
| 2023 Q4 | -31.55 Million USD | -52.67% |
| 2023 Q2 | -23.65 Million USD | -0.97% |
| 2023 FY | -108.85 Million USD | -21.4% |
| 2022 Q4 | -5.66 Million USD | 82.93% |
| 2022 Q1 | -35.24 Million USD | 10.0% |
| 2022 Q2 | -34.07 Million USD | 3.32% |
| 2022 Q3 | -33.16 Million USD | 2.69% |
| 2022 FY | -89.66 Million USD | -4.95% |
| 2021 Q4 | -39.16 Million USD | 7.56% |
| 2021 Q1 | -19.9 Million USD | 49.17% |
| 2021 FY | -85.43 Million USD | 0.0% |
| 2021 Q2 | -37.48 Million USD | -88.28% |
| 2021 Q3 | -42.36 Million USD | -13.04% |
| 2020 Q1 | 14.41 Million USD | 137.44% |
| 2020 FY | -85.43 Million USD | 30.85% |
| 2020 Q2 | -33.03 Million USD | -329.19% |
| 2020 Q3 | -29.35 Million USD | 11.13% |
| 2020 Q4 | -39.16 Million USD | -33.42% |
| 2019 Q4 | -38.49 Million USD | -44.44% |
| 2019 Q3 | -26.65 Million USD | 24.13% |
| 2019 FY | -123.55 Million USD | -17.57% |
| 2019 Q2 | -35.12 Million USD | -51.94% |
| 2019 Q1 | -23.11 Million USD | 21.0% |
| 2018 Q4 | -29.26 Million USD | -1.25% |
| 2018 FY | -105.09 Million USD | -13.43% |
| 2018 Q3 | -28.9 Million USD | -33.22% |
| 2018 Q2 | -21.69 Million USD | 12.87% |
| 2018 Q1 | -24.9 Million USD | 10.3% |
| 2017 FY | -92.65 Million USD | -44.85% |
| 2017 Q1 | -19.81 Million USD | -0.04% |
| 2017 Q2 | -20.63 Million USD | -4.13% |
| 2017 Q3 | -25.7 Million USD | -24.55% |
| 2017 Q4 | -27.76 Million USD | -8.01% |
| 2016 Q4 | -19.8 Million USD | -52.81% |
| 2016 FY | -63.96 Million USD | -109.51% |
| 2016 Q2 | -11.14 Million USD | 51.82% |
| 2016 Q1 | -23.13 Million USD | -1852.78% |
| 2016 Q3 | -12.96 Million USD | -16.33% |
| 2015 Q1 | -3.85 Million USD | -766.17% |
| 2015 Q4 | 1.31 Million USD | 108.72% |
| 2015 FY | -30.52 Million USD | -378.67% |
| 2015 Q3 | -15.13 Million USD | -11.25% |
| 2015 Q2 | -13.6 Million USD | -252.98% |
| 2014 FY | -6.37 Million USD | 92.09% |
| 2014 Q4 | -444.83 Thousand USD | -385.4% |
| 2014 Q3 | 155.86 Thousand USD | 104.55% |
| 2014 Q2 | -3.42 Million USD | 0.64% |
| 2014 Q1 | -3.44 Million USD | 39.19% |
| 2013 Q2 | -9.88 Million USD | -1.46% |
| 2013 FY | -80.62 Million USD | -208.43% |
| 2013 Q1 | -9.74 Million USD | 0.0% |
| 2013 Q3 | -5.56 Million USD | 43.68% |
| 2013 Q4 | -5.66 Million USD | -1.75% |
| 2012 FY | -26.13 Million USD | -3.29% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | -25.3 Million USD | -65.97% |
| 2010 FY | -15.24 Million USD | -12.99% |
| 2009 FY | -13.49 Million USD | -181.31% |
| 2008 FY | -4.79 Million USD | 38.35% |
| 2007 FY | -7.78 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.84 Million USD | -509.948% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -27842.95% |
| Nascent Biotech, Inc. | -2.22 Million USD | -4781.76% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -26100.446% |
| Qrons Inc. | -643.67 Thousand USD | -16811.797% |
| Rebus Holdings, Inc. | -664 Thousand USD | -16294.179% |
| Skye Bioscience, Inc. | -13.67 Million USD | -696.218% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 232.993% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -96.111% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -585.943% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -2057.949% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -8051.477% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -51.641% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 2314.884% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -41492.104% |
| SQZ Biotechnologies Company | -75.82 Million USD | -43.564% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -3718.877% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -6986.841% |
| Mesoblast Limited | -84.14 Million USD | -29.366% |
| Marizyme, Inc. | -34.08 Million USD | -219.356% |
| Genus plc | 6.4 Million USD | 1800.896% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 1217.35% |
| Pharming Group N.V. | -4.87 Million USD | -2130.892% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -5379.914% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -11587.748% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -1203.681% |
| ContraFect Corporation | -56.88 Million USD | -91.35% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -2289.987% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -7664.483% |
| IMV Inc. | -38.67 Million USD | -181.492% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -3857.242% |
| MultiCell Technologies, Inc. | -722.81 USD | -15060199.387% |
| ONE Bio Corp. | 13.68 Million USD | 895.651% |
| Accustem Sciences Inc. | -3.74 Million USD | -2805.637% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -84.535% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -22434.861% |
| Q BioMed Inc. | -3.44 Million USD | -3059.3% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 3175.066% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -4042.966% |
| Biomind Labs Inc. | -1 Million USD | -10682.194% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -98.022% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -3652.084% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -1537.441% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -5738.828% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -363339.336% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -5532.66% |
| GB Sciences, Inc. | -1.42 Million USD | -7563.264% |
| Alpha Cognition Inc. | -9.7 Million USD | -1021.593% |
| HST Global, Inc. | -140.9 Thousand USD | -77154.75% |
| CSL Limited | 3.7 Billion USD | 102.941% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -9577.017% |
| Halberd Corporation | -75.05 Thousand USD | -144946.436% |
| Enzolytics Inc. | -2.14 Million USD | -4965.96% |
| Agentix Corp. | -1.37 Million USD | -7835.62% |
| Resverlogix Corp. | -12.74 Million USD | -753.85% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -3335.857% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 74.389% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -10326.949% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -3628.701% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -6792.519% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -3097.005% |
| AVAX Technologies, Inc. | 6.69 Million USD | 1726.465% |
| Zenith Capital Corp. | -8.94 Million USD | -1117.235% |
| Genscript Biotech Corporation | -415.79 Million USD | 73.819% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -624762.809% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -4333.535% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -63370.143% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -5329.952% |
| Kadimastem Ltd | -3.04 Million USD | -3480.539% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -10962.143% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -8566.986% |
| BioStem Technologies, Inc. | -7.77 Million USD | -1299.38% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -59881.459% |
| LadRx Corporation | -3.82 Million USD | -2746.966% |
| Cell Source, Inc. | -4.32 Million USD | -2416.732% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -15746.474% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -15746.474% |
| NovAccess Global Inc. | -2.46 Million USD | -4312.969% |
| Affymax, Inc. | -15.04 Million USD | -623.497% |
| Itoco Inc. | -919.14 Thousand USD | -11743.392% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -2468.351% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -9628.092% |
| Mobile Lads Corp. | -554.55 Thousand USD | -19529.853% |
| CytoDyn Inc. | -18.05 Million USD | -502.821% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -432388.478% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -49363.077% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -19176.238% |
| SYBLEU INC | -149.18 Thousand USD | -72870.472% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -5893.291% |
| International Stem Cell Corporation | -663 Thousand USD | -16318.906% |
| Bioxytran, Inc. | -3.82 Million USD | -2749.559% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -206695.878% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -535088.545% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -200.164% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -6627.896% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -14693.717% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -3399.111% |
| Neutra Corp. | -229.48 Thousand USD | -47335.29% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -520.659% |
| PureTech Health plc | -146.19 Million USD | 25.542% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -406.522% |
| IXICO plc | -1.43 Million USD | -7475.32% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -1046.953% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 10.631% |
| CSL Limited | 3.81 Billion USD | 102.856% |